Know Cancer

forgot password

Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial

Phase 4
18 Years
Open (Enrolling)
Chronic Allograft Nephropathy

Thank you

Trial Information

Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial

Renal transplantation is the most effective form of treatment for end-stage renal failure.
It doubles long-term survival and has major socioeconomic and health benefits compared to
patients who remain on dialysis. Graft survival in the UK is 90% at one year and greater
than 75% at 5 years [UKTransplant, 2004], with better survival of grafts from living donors
compared with deceased. However, by 15 years post-transplantation, over 50% of recipients
who are still alive have returned to dialysis. Indeed, premature allograft failure is now
one of the leading causes of end stage renal disease. As short-term outcomes of renal
transplantation continue to improve, increasing attention is being paid to this late
attrition of renal allografts.

It is recognised that calcineurin inhibitor (CNI) nephrotoxicity is a major factor in late
renal allograft failure and dysfunction. In fact, withdrawal of CNI from patients with
deteriorating graft function may improve graft function. However, there is abundant evidence
that histological renal allograft damage may progress even in the absence of changes in
renal function - i.e. declining renal function is a late marker of renal damage, and
therefore institution of therapies (including CNI minimisation) to slow this process may be
"too little, too late".

CNI minimisation may be optimised by three major routes. Firstly, by minimising the CNI
beyond 12 months post transplantation when the risk of acute rejection is at its greatest.
Secondly, by performing a renal biopsy in patients prior to CNI minimisation and avoiding
CNI minimisation in patients with inflammation on the biopsy. Finally, converting
azathioprine to mycophenolate prior to CNI minimisation should have a renoprotective effect.

The type of CNI we will investigate is cyclosporine.

Patients who fulfill the study entry criteria will require a renal allograft biopsy prior to
randomisation to exclude acute rejection, recurrent disease or de novo glomerulonephritis.
Those patients with an acceptable biopsy will proceed to randomisation on a 1:1 basis into 2

Group 1: CNI [Cyclosporine] minimisation; Group 2: CNI [Cyclosporine] withdrawal.

At this point participants will undergo assessment of the primary and secondary outcome
measures. The treatment period comprises three stages:

Firstly, a 2 week period during which the patient will be stabilised on mycophenolate sodium
720mg twice daily (in place of azathioprine);

Secondly, a 3 month period during which the CNI [Cyclosporine} will be either targeted to a
specified low blood level of 50-100ng/ml, or withdrawn completely (depending on

Thirdly, a 12 month maintenance period on the new immunosuppression regimen.

During the first two stages, patients will be reviewed every 2 weeks. This 2-weekly
follow-up will continue for the first two months of the third stage of the study, and then
visits will be reduced to monthly. At these visits routine blood and urine analysis will be
performed as per routine clinical practice.

At the end of the third stage of the study (i.e. 16 months after randomisation) the
participants will undergo the second assessment of the primary and secondary outcome
measures. This will signify study end for the individual study participant.

Inclusion Criteria:

- The patient must be an adult recipient of a first kidney transplant

- A functioning kidney allograft with estimated (e)GFR by MDRD > 30 ml/min/1.73 m2, and
be between 1 and 5 years post transplantation

- Stable allograft function, as defined by no greater than 10% rise in serum creatinine
in the preceding 6 months, on cyclosporine and azathioprine based immunosuppression

- Minimal proteinuria, evidenced as urine albumin: creatinine ratio < 50 mg/mmol

Exclusion Criteria:

- > = 18 years of age

- Pregnancy or suspicion of pregnancy confirmed by positive b-HCG pregnancy test

- Female patients unwilling to take effective contraception for study duration

- Untreated ureteric obstruction on ultrasound of allograft

- Recurrent urosepsis

- Severe systemic infection

- Untreated significant (> 50%) renal artery stenosis on magnetic resonance angiography
performed prior to study

- History of acute allograft rejection

- History of myocardial infarction

- History of malignancy in previous 5 years (excluding non-melanomatous tumours limited
to skin)

- Symptomatic ischaemic heart disease

- Hepatitis B surface antigen positive, Hepatitis C positive, or HIV positive

- Recipient of combined organ transplantation (e.g. pancreas/kidney; liver/kidney)

- Recipient of ABO-incompatible kidney

- Greater than 1 HLA mismatch at either the "B" or "DR" locus

- Peak HLA antibody Panel Reactivity (PRA) greater than 10%

- Recipient who underwent HLA desensitisation procedure prior to transplantation

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

To compare renal allograft markers of damage and evolving injury in biopsies immediately pre study and at the end of the study

Outcome Time Frame:

16 months

Principal Investigator

Richard Borrows, MRCP

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital Birmingham NHS Foundation Trust


United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:




Start Date:

October 2007

Completion Date:

February 2010

Related Keywords:

  • Chronic Allograft Nephropathy
  • Renal Transplantation
  • Calcineurin Inhibitor
  • Cyclosporine
  • Withdrawal
  • Minimisation
  • Kidney Diseases